ReviewESC heart failure2023
Gastrointestinal bleeding on continuous-flow left ventricular assist device therapy.
Review in ESC heart failure, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 18 citations in OpenAlex.
- Successful Hemostasis by Double-balloon Enteroscopy with Mini-laparotomy for Small-bowel Hemorrhage in a Patient with LVAD.Internal medicine (Tokyo, Japan) · 2026Article
- Co-designing emergency communication for patients with mechanical circulatory support devices.JHLT open · 2026Article
- Driveline Infections in Durable LVAD Support: Risk Factors, Microbiology, and Resistance Patterns from a Large Cohort.Diagnostics (Basel, Switzerland) · 2026Article
- Long-term outcomes of patients implanted with a HeartMate 3 left ventricular assist device-a real-world, single-centre, observational study.ESC heart failure · 2026Observational
- Article
- Advancing antithrombotic therapies for left ventricular assist devices: challenges, innovations, and future perspectives.Future cardiology · 2025Article
- Durable left ventricular assist devices in pediatrics: impact of body size on outcomes and size limitations.Journal of artificial organs : the official journal of the Japanese Society for Artificial Organs · 2025Review
- Recent Developments in Ventricular Assist Device Therapy.Reviews in cardiovascular medicine · 2025Review
- Gastrointestinal bleeding on continuous-flow left ventricular assist device therapy.ESC heart failure · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
While technological advances in the field of continuous-flow left ventricular assist device (CF-LVAD) are constantly being made, CF-LVAD recipients are still subjected to a relatively high rate of LVAD-related adverse events, with post-LVAD gastrointestinal bleeding (GIB) being the most common one. GIB is associated with a significant impairment in quality of life, multiple hospital admissions, blood transfusion requirements and possibly death. Furthermore, of those patients who bled once, many will experience recurrent GIB events, which further aggravates their discomfort. While some medical and endoscopic treatment options are available, evidence regarding their benefit remains largely equivocal, with all related studies based on data from registries rather than clinical trials. Although having a major impact on LVAD recipients, an effective and validated pre-implant screening options to predict GIB events post-implant are scarce. This review focuses on the aetiology, incidence, risk factors, treatment options and the effect of new generation devices on post-LVAD GIB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.